Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC

Cited by (1,002)

Items 801–900 of 1,002

1. Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)
   Elio Gregory Pizzutilo, Alberto Giuseppe Agostara, Sara Oresti, Diego Signorelli, Stefano Stabile, Calogero Lauricella, Valentina Motta, Alessio Amatu, Lorenzo Ruggieri, Marta Brambilla et al. · 2024 · ESMO Open
2. Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer
   Zhen Chen, Karin A. Vallega, Dongsheng Wang, Zihan Quan, Songqing Fan, Qiming Wang, Ticiana A.B. Leal, Suresh S. Ramalingam, Shi‐Yong Sun · 2024 · The Journal of Experimental Medicine
3. Resistance mechanisms of non-small cell lung cancer and improvement of treatment effects through nanotechnology: a narrative review
   Zhenyu Cao, Jiaqi Zhu, Xingyou Chen, Zhijian Chen, Weixin Wang, Youlang Zhou, Yuchen Hua, Jiahai Shi, Jianle Chen · 2024 · Journal of Thoracic Disease
4. Evolving treatment for advanced non-small cell lung cancer harbouring common EGFR activating mutations
   Igor Gomez-Randulfe, Federico Monaca, David Planchard, Emilio Bria, Raffaele Califano · 2025 · Critical Reviews in Oncology/Hematology
5. In silico exploration of anticancer plant phytochemicals for EGFR-targeted lung cancer therapy
   Chaity Debnath Dipa, Sharika Hossain, Md. Moinul Karim Chy, Mohammad Sheikh Farider Rahman, Tanvir Kayes, Afia Maimuna Easha, Abu Tayab Moin, Suvarna N. Vakare, Rajesh B. Patil, Bidduth Kumar Sarkar · 2025 · Scientific Reports
6. Optimal sequencing strategies in the treatment of EGFR mutation–positive non–small cell lung cancer: Clinical benefits and cost-effectiveness
   Vera Hirsh, Jaspal Ricky Singh · 2020 · American Journal of Health-System Pharmacy
7. A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1
   Cheol‐Kyu Park, Hyun-Ju Cho, Yoo Duk Choi, In‐Jae Oh, Young‐Chul Kim · 2020 · Cancer Research and Treatment
8. Combined Inhibition of EGFR and VEGF Pathways in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
   Monica Peravali, Haijun Wang, Chul Kim, Irina G. Veytsman · 2020 · Current Oncology Reports
9. Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting
   Qianqian Wang, Wen Gao, Fangyan Gao, Shidai Jin, Tianyu Qu, Fan Lin, Chen Zhang, Jingya Zhang, Zhihong Zhang, Liang Chen et al. · 2021 · BMC Cancer
10. Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer
    Shuta Ohara, Kenichi Suda, Toshio Fujino, Akira Hamada, T. Koga, Masaya Nishino, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Junichi Soh et al. · 2021 · Lung Cancer
11. Management of Oligometastasis and Oligoprogression in Patients with Epidermal Growth Factor Receptor Mutation-Positive NSCLC in the Era of Third-Generation Tyrosine Kinase Inhibitors
    Jeong Uk Lim · 2021 · Clinical Lung Cancer
12. Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with EGFR-Mutated Non-Small-Cell Lung Cancer Regardless of Cerebrospinal Fluid T790M Mutational Status
    Milan Zhang, Weifeng Ma, Huiqin Liu, Yushu Jiang, Lingzhi Qin, Wei Li, Jiewen Zhang · 2021 · Evidence-based Complementary and Alternative Medicine · Retracted
13. A call to action: molecular pathology in Brazil
    Isabela Werneck da Cunha, Renata de Almeida Coudry, Mariana Petaccia de Macêdo, Emílio Augusto Campos Pereira de Assis, Stephen Doral Stefani, Fernando Augusto Soares · 2021 · Surgical and Experimental Pathology
14. Identification of Targetable Liabilities in the Dynamic Metabolic Profile of EGFR-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance
    Αναστάσιος Γκουντάκος, Giovanni Centonze, Emanuele Vita, Lorenzo Belluomini, Michèle Milella, Emilio Bria, Massimo Milione, Aldo Scarpa, Michele Simbolo · 2022 · Biomedicines
15. Brain metastasis: Recent treatment modalities and future‑perspectives (Review)
    Atsuto Katano, Hideomi Yamashita · 2022 · Oncology Letters
16. Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes
    Elizabeth A. Coker, Adam Stewart, Buğra Özer, Anna Rachel Minchom, Lisa Pickard, Ruth R. Ruddle, Suzanne Carreira, Sanjay Popat, Mary E.R. O'Brien, Florence I. Raynaud et al. · 2022 · Molecular Cancer Therapeutics
17. L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment
    Meihui Li, Jing Qin, Fajun Xie, Lei Gong, Na Han, Hongyang Lu · 2022 · Discover Oncology
18. Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status
    Tetsuya Isaka, Hiroyuki Ito, Tomoyuki Yokose, Haruhiro Saito, Hiroyuki Adachi, Kotaro Murakami, Jun Miura, Noritake Kikunishi, Yasushi Rino · 2022 · BMC Cancer
19. Liquid Biopsy Analysis as a Tool for TKI-Based Treatment in Non-Small Cell Lung Cancer
    Karolina Buszka, Aliki Ntzifa, Barbara Owecka, Paula Kamińska, Agata Kolecka-Bednarczyk, Maciej Zabel, Michal O. Nowicki, Evi S. Lianidou, Joanna Budna · 2022 · Cells
20. Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas
    Siliang Chen, Shuxin Zhang, Zhihao Wang, Junhong Li, Yunbo Yuan, Tengfei Li, Mingrong Zuo, Wentao Feng, Wenhao Li, Mina Chen et al. · 2022 · Frontiers in Pharmacology
21. Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer
    Andre Verhoek, Parneet Kaur Cheema, Barbara L. Melosky, Benoit Samson, Frances A. Shepherd, Filippo de Marinis, Thomas John, Yi-Long Lung Cancer Wu, Bart M. S. Heeg, Nadia Van Dalfsen et al. · 2023 · PharmacoEconomics - Open
22. Characterization of circRNAs in established osimertinib‑resistant non‑small cell lung cancer cell lines
    Xin Chen, Jingyao Gu, Jiali Huang, Kang Wen, Ge Zhang, Zhenyao Chen, Zhaoxia Wang · 2023 · International Journal of Molecular Medicine
23. The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer
    Florian Wittlinger, Stefan Laufer · 2021 · Expert Opinion on Drug Discovery
24. Advances in Targeted Therapy for Non-Small-Cell Lung Cancer: Current Progress and Future Directions
    Supriya Peshin, Ehab Takrori, Joseph H. Yazji, J. Haque, Adit Alpesh Dharia, Mohammad Sajid Mithani, Fnu Anum, Ummul Zohra Asfeen, Jill Kristen Couch, Mabe Donovan et al. · 2025 · International Journal of Molecular Sciences
25. Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC
    Tara L. Peters, Tejas Patil, Anh Tuan Le, Kurtis D. Davies, Peter M. Brzeskiewicz, Hala Nijmeh, Liming Bao, D. Ross Camidge, Dara L. Aisner, Robert Charles Doebele · 2021 · npj Precision Oncology
26. Cost-Effectiveness of 12 First-Line Treatments for Patients With Advanced EGFR Mutated NSCLC in the United Kingdom and China
    Haijing Guan, Chunping Wang, Chen Chen, Sheng Han, Zhigang Zhao · 2022 · Frontiers in Oncology
27. Immunoregulatory framework and the role of miRNA in the pathogenesis of NSCLC – A systematic review
    Nikhil H. Samarth, Pooja Gulhane, Shailza Singh · 2022 · Frontiers in Oncology
28. Genomics of Breast Cancer Brain Metastases: A Meta-Analysis and Therapeutic Implications
    Thuy Thu Nguyen, Diaddin Hamdan, Eurydice Angeli, Jean‐Paul Feugeas, Quang Van Le, Frédéric Pamoukdjian, Guilhem Bousquet · 2023 · Cancers
29. Molecular residual disease: A new clue for individualized approach in non‐small cell lung cancer
    Jia‐Tao Zhang, Wen‐Zhao Zhong, Yi-Long Wu · 2023 · Medicine Advances
30. CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC
    Alexandria TM Lee, Misako Nagasaka · 2023 · Lung Cancer Targets and Therapy
31. Circulating tumor DNA (ctDNA)-based minimal residual disease in non-small cell lung cancer
    Li-Bo Tang, Ruiyang Li, Huahai Wen, Qing Hua Zhou, Chong‐Rui Xu · 2023 · Chinese Medical Journal - Pulmonary and Critical Care Medicine
32. Cancer Drugs Reimbursed with Limited Evidence on Overall Survival and Quality of Life: Do Follow-Up Studies Confirm Patient Benefits?
    Gabriella Chauca Strand, Naimi Johansson, Niklas Jakobsson, Carl Bonander, Mikael Svensson · 2023 · Clinical Drug Investigation
33. Prognostic Factors and Markers in Non-Small Cell Lung Cancer: Recent Progress and Future Challenges
    Débora Dummer Meira, Maria Clara de Castro e Caetano, Matheus Correia Casotti, Aléxia Stefani Siqueira Zetum, André Felipe Monteiro Gonçalves, André Rodrigues Moreira, Augusto Henrique de Oliveira, Fellipe Pesente, Gabriel Mendonça Santana, Daniel de Almeida Duque et al. · 2023 · Genes
34. Exploring the impact of patient‐specific clinical features on osimertinib effectiveness in a real‐world cohort of patients with EGFR mutated non‐small cell lung cancer
    Ard van Veelen, G. Veerman, Marjon V. Verschueren, Judith L. Gulikers, Christi M. J. Steendam, A. Brouns, Safiye Dursun, Marthe S. Paats, Vivianne C. G. Tjan‐Heijnen, Cor van der Leest et al. · 2023 · International Journal of Cancer
35. Clinical application of the Lung Cancer Compact PanelTM using various types of cytological specimens in patients with lung cancer
    Kei Kunimasa, Motohiro Tamiya, Takako Inoue, Takahisa Kawamura, Akito Miyazaki, Yoshiki Kojitani, Keiichiro Honma, Kazumi Nishino · 2024 · Lung Cancer
36. A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer
    Mai Suzuki, Ken Uchibori, Tomoko Oh‐hara, Yumi Nomura, Ryusei Suzuki, Ai Takemoto, Mitsugu Araki, Shigeyuki Matsumoto, Yukari Sagae, Mutsuko Kukimoto‐Niino et al. · 2024 · npj Precision Oncology
37. YBX1 as a prognostic biomarker and potential therapeutic target in hepatocellular carcinoma: A comprehensive investigation through bioinformatics analysis and in vitro study
    Zizhen Li, Wenhua Lu, Feng Yin, A.C.C. Huang · 2024 · Translational Oncology
38. Navigating the Complexities of Brain Metastases Management
    Afsaneh Amouzegar, Shannon Haig, Adriana Matutino Kahn, Hussein A. Tawbi, Joshua Jones, Sarah B. Goldberg · 2024 · American Society of Clinical Oncology Educational Book
39. Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms—An In Vitro Study
    Shota Fukuda, Kenichi Suda, Akira Hamada, Hana Oiki, Shuta Ohara, Masaoki Ito, Junichi Soh, Tetsuya Mitsudomi, Yasuhiro Tsutani · 2024 · Biomedicines
40. Molecular and functional landscape of malignant serous effusions for precision oncology
    Rebekka Wegmann, Lorenz Bankel, Yasmin Festl, Kate Lau, Sohyon Lee, Fabian M. Arnold, Valentina Cappelletti, Aaron Fehr, Paola Picotti, Konstantin Johannes Dedes et al. · 2024 · Nature Communications
41. Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment
    Aliki Ntzifa, Theodoros Marras, Galatea Kallergi, Athanasios Panayotis Kotsakis, Vassilis Georgoulias, Evi S. Lianidou · 2024 · Frontiers in Oncology
42. EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis
    Ao Liu, Xiaoming Wang, Lian Wang, Zhuang Han, Liubo Xiong, Xiao Gan, Qian Wang, Guanyu Tao · 2024 · BMC Cancer
43. Oligometastatic NSCLC: Current Perspectives and Future Challenges
    Sara Torresan, Jacopo Costa, Carol Zanchetta, Lorenzo De Marchi, Simona Rizzato, Francesco Cortiula · 2025 · Current Oncology
44. Drug Resistance in Late-Stage Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Patients After First-Line Treatment with Tyrosine Kinase Inhibitors
    Ching‐Yi Lee, Shih‐Wei Lee, Yi‐Chiung Hsu · 2025 · International Journal of Molecular Sciences
45. Multi-omic profiling in breast cancer: utility for advancing diagnostics and clinical care
    Emna El Gazzah, Scott Parker, Mariaelena Pierobon · 2025 · Expert Review of Molecular Diagnostics
46. Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review
    Luca Sala, Maddalena Mancin, Alessia Pastore, Davide Seminati, Diego Luigi Cortinovis, Paolo Bidoli, Andrea Alberti · 2020 · Lung Cancer
47. Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: a new algorithm for patient selection and personalized treatment
    Fiamma Buttitta, Lara Felicioni, Alessia Di Lorito, Alessio Cortellini, Luciana Irtelli, Davide Brocco, Pietro Di Marino, Donatella Traisci, Nicola D’Ostilio, Alessandra Di Paolo et al. · 2020 · Oncotarget
48. Duration of Targeted Therapy in Patients With Advanced Non–small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis
    Karen L. Reckamp, Tejas Patil, Kedar Kirtane, Thereasa A. Rich, Carin R. Espenschied, Caroline M. Weipert, Victoria M. Raymond, Rafael Santana-Dávila, Robert Charles Doebele, Christina S. Baik · 2020 · Clinical Lung Cancer
49. A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment
    Karthick Vishwanathan, Inmaculada Sanchez-Simon, Bhumsuk Keam, Nicolas Penel, Maria José De Miguel, Doris K. Weilert, Andrew Mills, Marcelo Marotti, Martin G. Johnson, Alain Ravaud · 2020 · Pharmacology Research & Perspectives
50. Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations
    Justin A. Chen, Jonathan Wesley Riess · 2020 · Current Treatment Options in Oncology
51. A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
    Chung‐Shien Lee, Sandhya Sharma, Emily Miao, Cheryl Mensah, Kevin M. Sullivan, Nagashree Seetharamu · 2020 · Lung Cancer Targets and Therapy
52. A Pilot Study: Changes of Intestinal Microbiota of Patients With Non-small Cell Lung Cancer in Response to Osimertinib Therapy
    Jing Cong, Yuguang Zhang, Yadong Xue, Chuantao Zhang, Mingjin Xu, Dong Liu, Ruiyan Zhang, Hua Zhu · 2020 · Frontiers in Microbiology
53. The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
    Fen Wang, Feng Jin, Boran Cheng, Yue Zhang, Qing Hua Zhou, Shubin Wang · 2021 · Journal of Cancer Research and Clinical Oncology
54. Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study
    Kinnosuke Matsumoto, Akihiro Tamiya, Yoshinobu Matsuda, Yoshihiko Taniguchi, Shinji Atagi, Hayato Kawachi, Motohiro Tamiya, Satoshi Tanizaki, Junji Uchida, Kiyonobu Ueno et al. · 2021 · Translational Lung Cancer Research
55. Real-World Data on Treatment Outcomes in EGFR -Mutant Non-Small-Cell Lung Cancer Patients Receiving Osimertinib in Second or Further Lines
    Alessandro Dal Maso, Martina Lorenzi, Alessandra Ferro, Sara Pilotto, Fabiana Letizia Cecere, Alessandro Follador, Valentina Polo, Alessandro Del Conte, Giulia Sartori, Marco Giavarra et al. · 2021 · Future Oncology
56. The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
    Yen-Hsiang Huang, Kuo-Hsuan Hsu, Chun-Shih Chin, Jeng‐Sen Tseng, Tsung‐Ying Yang, Kun‐Chieh Chen, Kang‐Yi Su, Sung‐Liang Yu, Jeremy J.W. Chen, Gee‐Chen Chang · 2021 · Cancer Research and Treatment
57. Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients
    John Wen‐Cheng Chang, Chen‐Yang Huang, Yueh‐Fu Fang, Ching‐Fu Chang, Cheng‐Ta Yang, Chih‐Hsi S. Kuo, Ping‐Chih Hsu, Chiao‐En Wu · 2022 · Thoracic Cancer
58. Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer
    Woraseth Saifon, Insee Sensorn, Narumol Trachu, Songporn Oranratnachai, Angkana Charoenyingwattana, Chakkaphan Runcharoen, Nanamon Monnamo, Warawut Sukkasem, Pimpin Inchareon, Thitiporn Suwatanapongched et al. · 2022 · BMC Cancer
59. Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer
    Hayato Yokota, Kazuhiro Sato, Sho Sakamoto, Yūji Okuda, Natsuki Fukuda, Mariko Asano, Masahide Takeda, Katsutoshi Nakayama, Masatomo Miura · 2022 · Investigational New Drugs
60. Molecular Profiling in Non-Squamous Non-Small Cell Lung Carcinoma: Towards a Switch to Next-Generation Sequencing Reflex Testing
    Nina Pujol, Simon Heeke, Christophe Bontoux, Jacques Boutros, Marius Ilié, Véronique Hofman, Charles‐Hugo Marquette, Paul M Hofman, Jonathan Benzaquen · 2022 · Journal of Personalized Medicine
61. Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
    Qiuyue Ye, Yan Xu, Jing Zhao, Xiaoxing Gao, Minjiang Chen, Ruili Pan, Wei Zhong, Mengzhao Wang · 2023 · Translational Oncology
62. Precision Surgery in NSCLC
    Giorgio Cannone, Giovanni Maria Comacchio, Giulia Pasello, Eleonora Faccioli, Marco Schiavon, Andrea Dell’Amore, Marco Mammana, Federico Rea · 2023 · Cancers
63. Analyses of single extracellular vesicles from non-small lung cancer cells to reveal effects of epidermal growth factor receptor inhibitor treatments
    Fredrik Stridfeldt, Sara Cavallaro, Petra Hååg, Rolf Lewensohn, Jan Linnros, Kristina Viktorsson, Apurba Dev · 2023 · Talanta
64. In situ modeling of acquired resistance to RTK/RAS-pathway-targeted therapies
    Nancy E. Sealover, Patricia L. Theard, Jacob M. Hughes, Amanda J. Linke, Brianna R. Daley, Robert L. Kortum · 2023 · iScience
65. A nanowire-based liquid biopsy method using cerebrospinal fluid cell-free DNA for targeted management of leptomeningeal carcinomatosis
    Wonyoung Choi, Youngnam Cho, Seog-Yun Park, Kum Hui Hwang, Ji‐Youn Han, Youngjoo Lee · 2020 · Journal of Cancer Research and Clinical Oncology
66. Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia
    Terence Khoo, Lan Gao · 2020 · Expert Review of Pharmacoeconomics & Outcomes Research
67. Exploring variables related to medical surrogate decision-making accuracy during the COVID-19 pandemic
    Rachael Spalding, Barry A. Edelstein · 2021 · Patient Education and Counseling
68. Emerging Therapies in Thoracic Malignancies—Immunotherapy, Targeted Therapy, and T-Cell Therapy in Non–Small Cell Lung Cancer
    Boris Sepesi, Tina Cascone, Stephen G. Chun, Mehmet Altan, Xiuning Le · 2020 · Surgical Oncology Clinics of North America
69. Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study
    Shi, Yuankai, Zhou, Jianying, Zhao, Yanqiu, Zhu, Bo, Zhang, Liangming, Li, Xingya, Fang, Jian, Shi, Jianhua, Zhuang, Zhixiang, Yang, Sheng et al. · 2023 · BMC Medicine
70. The American Cancer Society National Lung Cancer Roundtable strategic plan: Advancing comprehensive biomarker testing in non–small cell lung cancer
    Adam H. Fox, Raymond Uyiosa Osarogiagbon, Farhood Farjah, James R. Jett, Bruce Evan Johnson, M. Patricia Rivera, Robert Allen Smith, Ignacio Ivan Wistuba, Gerard A. Silvestri · 2024 · Cancer
71. High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models
    Juan Carlos Álvarez-Pérez, Juan Sanjuán‐Hidalgo, Alberto M. Arenas, Ivan Hernández-Navas, Maria S. Benitez‐Cantos, Álvaro Andrades, Silvia Calabuig Fariñas, Eloisa Jantus Lewintre, Luis G Paz-Ares, Irene Ferrer et al. · 2025 · Nature Communications
72. Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitor
    Yeong Hak Bang, Geun‐Ho Park, Jin Woo Oh, Soohyun Hwang, Jun-Gi Jeong, Boram Lee, Cheol Yong Joe, Hye Min Kim, Jinyong Kim, Sehhoon Park et al. · 2025 · Journal for ImmunoTherapy of Cancer
73. A tumor-derived lactate/ENO1 lactylation feedback loop facilitates osimertinib resistance of lung adenocarcinoma
    Gan Lu, Qihai Sui, Mi‐die Xu, Fei Yang, Ming Li, Yitao Yuan, Yufu Lin, Xiuping Zhang, Guoshu Bi, Wei Jiang et al. · 2025 · Drug Resistance Updates
74. Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD
    Jonathan Wesley Riess, H.A. Yu, Xiuning Le, A.J. de Langen, B.C. Cho, Z. Piotrowska, Lizza E.L. Hendriks, A. Morabito, L. Bonanno, Odd Terje Brustugun et al. · 2026 · Annals of Oncology
75. Montelukast Inhibits Lung Cancer Cell Migration by Suppressing Cysteinyl Leukotriene Receptor 1 Expression In vitro
    Shuo Wei, Yisheng Chen, Jinye Zhang · 2022 · Current Pharmaceutical Biotechnology
76. Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non‐small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study
    Simon Ekman, Zsolt Cselényi, Andrea Varrone, Aurelija Jučaitė, Heather Martin, Magnus Schou, Peter Johnström, Gianluca Laus, Rolf Lewensohn, Andrew P. Brown et al. · 2023 · Clinical and Translational Science
77. SOX1 Functions as a Tumor Suppressor by Repressing HES1 in Lung Cancer
    Shan‐Yueh Chang, Ti-Hui Wu, Yu‐Lueng Shih, Ying‐Chieh Chen, Her‐Young Su, Chih‐Feng Chian, Ya‐Wen Lin · 2023 · Cancers
78. A Prospective Cohort Study Assessing the Relationship between Plasma Levels of Osimertinib and Treatment Efficacy and Safety
    Tatsuro Fukuhara, Kazuhiro Imai, Taku Nakagawa, Ryotaro Igusa, Hayato Yokota, Kana Watanabe, Aya S. Suzuki, Mami Morita, Ren Onodera, Akira Inoue et al. · 2023 · Biomedicines
79. Precision nanomedicine to treat non-small cell lung cancer
    Akanksha D. Dessai, Usha Y. Nayak, Yogendra Nayak · 2024 · Life Sciences
80. Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%–89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab
    Biagio Ricciuti, Arielle Elkrief, Jessica Lin, Jianjun J. Zhang, Joao V. Alessi, Giuseppe Lamberti, Malini Marion Gandhi, Alessandro Di Federico, Federica Pecci, Xinan Wang et al. · 2024 · JTO Clinical and Research Reports
81. First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials
    Thierry Landre, Jean‐Baptiste Assié, Kader Chouahnia, Gaëtan Des Guetz, J.B. Auliac, CHRISTOS CHOUAID · 2024 · Expert Review of Anticancer Therapy
82. Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives
    Hang Zhang, Yingying Zhang, Yingying Zhu, Tian Dong, Zheng Liu · 2024 · Frontiers in Oncology
83. Optimization of treatment strategies for elderly patients with advanced non-small cell lung cancer
    Qiang Chen, Shuo Ying, Jianwen Qin, Li Zhang · 2024 · Frontiers in Oncology
84. Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario
    Valeria Fuorivia, Ilaria Attili, Carla Corvaja, Riccardo Asnaghi, Ambra Carnevale Schianca, Pamela Trillo Aliaga, Ester Del Signore, Gianluca Spitaleri, Antonio Passaro, Filippo de Marinis · 2024 · Current Oncology
85. The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study)
    Kageaki Watanabe, Yukio Hosomi, Katsuhiko Naoki, Yoshiro Nakahara, Yoko Tsukita, Hirotaka Matsumoto, Kiyotaka Yoh, Yasuhito Fujisaka, Satoshi Takahashi, Saori Takata et al. · 2024 · JTO Clinical and Research Reports
86. MET tyrosine kinase inhibitors in combination with EGFR tyrosine kinase inhibitors in NSCLC patients with EGFR mutations and acquired MET alterations: a systematic review and meta-analysis
    Defeng Hu, Yixuan Hu, Shipeng Lei, Dong‐Dong Wu, Yubo Wang · 2025 · BMC Cancer
87. Long non-coding RNA LRTOR drives osimertinib resistance in non-small cell lung cancer by boosting YAP positive feedback loop
    Zhimin Miao, Sha Zhou, Jianzhong He, Yongkai Liang, Lihua Tan, Yuxin Zhao, Xiaobing Cui, Jinmiao Zhong, Ruting Zhong, Huijun Liang et al. · 2025 · Drug Resistance Updates
88. EGFR mutation-positive NSCLC: factors to consider when deciding first-line therapy
    Pauline Hulo, Dahna Coupez, Marc Guillaume Denis, Jaafar Bennouna · 2020 · Expert Review of Anticancer Therapy
89. Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment
    Akira Nakao, Osamu Hiranuma, Junji Uchino, Chikara Sakaguchi, Tomoyuki Araya, Noriya Hiraoka, Tamotsu Ishizuka, Takayuki Takeda, Masayuki Kawasaki, Yasuhiro Gotô et al. · 2020 · Journal of Clinical Medicine
90. Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database
    Keigo Kobayashi, Kenzo Soejima, Koichi Fukunaga, Yasushi Shintani, Ikuo Sekine, Takehito Shukuya, Koichi Takayama, Akira Inoue, Isamu Okamoto, Katsuyuki Kiura et al. · 2020 · Lung Cancer
91. Prognostic Impact of Smoking Period in Patients with Surgically Resected Non-small Cell Lung Cancer
    Shinkichi Takamori, Mototsugu Shimokawa, Taichi Matsubara, Naoki Haratake, Ryo Toyozawa, Naoko Miura, Masafumi Yamaguchi, Takashi Seto, Tetsuzo Tagawa, Tatsuro Okamoto et al. · 2020 · Annals of Surgical Oncology
92. Optimizing Therapy Sequence to Prevent Patient Attrition in EGFR Mutation-Positive Advanced or Metastatic NSCLC
    Julia Roeper, Sylke Kurz, Christian Grohé, Frank Griesinger · 2020 · Future Oncology
93. Highly Sensitive Droplet Digital PCR Method for Detection of de novo EGFR T790M Mutation in Patients with Non-Small Cell Lung Cancer
    Xun Wang, Xiao Li, Haifa Guo, Lingxiang Zhu, Zhiyong Peng, Jun Wang, Fan Yang, Yong Sheng Guo · 2020 · OncoTargets and Therapy
94. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis
    Santiago Ponce Aix, Silvia Novello, Edward B. Garon, Kazuhiko Nakagawa, Ernest Nadal, Denis Moro‐Sibilot, Miriam Alonso García, Elizabeth Fabre, Bente Frimodt‐Moller, AH Zimmermann et al. · 2021 · Cancer Treatment and Research Communications
95. Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status
    Haiyan Xu, Hengqi Chen, Jian-xin Kong, Ye Zhang, Shan Liu, Guangjian Yang, Lu Yang, Yan Wang · 2021 · Annals of Translational Medicine
96. The role of comprehensive analysis with circulating tumor DNA in advanced non‐small cell lung cancer patients considered for osimertinib treatment
    Naoko Sueoka‐Aragane, Chiho Nakashima, Hironori Yoshida, Naohisa Matsumoto, Kentaro Iwanaga, Noriyuki Ebi, Akihiro Nishiyama, Kazuhiro Yatera, Shoichi Kuyama, Minoru Fukuda et al. · 2021 · Cancer Medicine
97. Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies
    Christiane Bickert, Kathrin Kahnert, Diego Erich Kauffmann-Guerrero, Jeremias Götschke, Zulfiya Syunyaeva, Jürgen Behr, Amanda Tufman · 2021 · Therapeutic Advances in Medical Oncology
98. Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer
    Pamela Abdayem, David Planchard · 2021 · European Respiratory Review
99. Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
    Taichi Miyawaki, Hirotsugu Kenmotsu, Hiroaki Kodama, Naoya Nishioka, Eriko Miyawaki, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Ryo Ko, Kazushige Wakuda et al. · 2021 · BMC Cancer
100. Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR -mutated non-small cell lung cancer treated with osimertinib
     Gianluca Taronna, Alessandro Leonetti, Filippo Gustavo Dall’Olio, Alessandro Rizzo, Claudia Parisi, Sebastiano Buti, Paola Bordi, Stefano Brocchi, Rita Golfieri, Andrea Ardizzoni et al. · 2021 · Tumori Journal